Avastin wows again in breast cancer trial as second-line agent
August 19th, 2009
Roche’s flagship cancer drug Avastin won yet another gold star yesterday after performing well in a late stage trial assessing its potential in extending progression free survival in women with breast cancer.
Currently, the drug is approved on both sides of the Atlantic as a treatment for colorectal cancer, non-small lung cancer, renal cell carcinoma and as a first-line therapy for breast cancer, while in the US it has also been cleared for glioblastoma.